Form 8-K - Current report:
SEC Accession No. 0001213900-25-044286
Filing Date
2025-05-15
Accepted
2025-05-15 16:31:29
Documents
15
Period of Report
2025-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0242203-8k_emmaus.htm   iXBRL 8-K 27306
2 MAY 15, 2025 PRESS RELEASE ea024220301ex99-1_emmaus.htm EX-99.1 34170
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3635
  Complete submission text file 0001213900-25-044286.txt   241905

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE emma-20250515.xsd EX-101.SCH 3029
5 XBRL LABEL FILE emma-20250515_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE emma-20250515_pre.xml EX-101.PRE 22368
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0242203-8k_emmaus_htm.xml XML 3359
Mailing Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503
Business Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 310-214-0065
Emmaus Life Sciences, Inc. (Filer) CIK: 0000822370 (see all company filings)

EIN.: 870419387 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35527 | Film No.: 25954189
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)